title: Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria.
abstract: Injury of the renal tubulointerstitial compartment is recognized to play an important role in hypertension. Its damage may in turn, impair the activity of vasodepressor systems, like the kallikrein-kinin, in blood pressure regulation. The overload proteinuria model induces tubulointerstitial injury with activation of the renin-angiotensin system, but renal kallikrein and the development of hypertension have not received special attention. Sprague-Dawley rats received seven intraperitoneal doses of bovine serum albumin (BSA) 2 g/day under normosodic diet and were hydrated ad libitum. A second group received a high potassium diet to stimulate kallikrein production during the previous four weeks and while under BSA administration. A third one received potassium and BSA in the same schedule, but with the kinin B2 receptor antagonist, HOE140, added during the protein load phase. A control group received seven saline injections. Kallikrein protein was detected by immune labeling on renal sections and enzymatic activity in the urine. The BSA group showed massive proteinuria followed by intense tubulointerstitial damage. Blood pressure increased after the third dose in BSA animals, remaining elevated throughout the experiment, associated with significant reductions in renal expression and urinary activity of kallikrein, compared with controls. An inverse correlation was found between blood pressure and immunohistochemistry and urinary activity of kallikrein. Potassium induced a significant increase in both urinary activity and renal kallikrein expression, associated with significant reduction in blood pressure. The HOE140 antagonist blunted the antihypertensive effect of kallikrein stimulation in proteinuric rats. Loss of renal kallikrein, produced by tubulointerstitial injury, may participate in the pathogenesis of the hypertension observed in this model.
authors.affiliation: Department of Nephrology, Universidad Austral de Chile, Valdiva, Chile. lardiles@uach.cl
authors.forename: L G
authors.initials: LG
authors.lastname: Ardiles
authors.forename: F
authors.initials: F
authors.lastname: Loyola
authors.forename: P
authors.initials: P
authors.lastname: Ehrenfeld
authors.forename: M E
authors.initials: ME
authors.lastname: Burgos
authors.forename: C A
authors.initials: CA
authors.lastname: Flores
authors.forename: G
authors.initials: G
authors.lastname: Valderrama
authors.forename: I
authors.initials: I
authors.lastname: Caorsi
authors.forename: J
authors.initials: J
authors.lastname: Egido
authors.forename: S A
authors.initials: SA
authors.lastname: Mezzano
authors.forename: C D
authors.initials: CD
authors.lastname: Figueroa
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D007610:Kallikreins / Q000096:biosynthesis* / Q000652:urine; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D017419:Potassium, Dietary / Q000008:administration & dosage*; D011507:Proteinuria / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012084:Renin-Angiotensin System / Q000502:physiology; D013599:Systole
chemical_list: D017419:Potassium, Dietary; C065679:icatibant; D007610:Kallikreins; D001920:Bradykinin